Forerunner Pharma Research Co., Ltd. (FPR) was founded as a joint venture by Chugai Pharmaceutical Co., Ltd., Mitsui & Co., Ltd., and Central Institute for Experimental Animals in April 2005. And then, In September 2011, FPR made a new start as a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.
FRP is a drug discovery laboratory engaged mainly in joint study with external research institutions. Currently, we are active at 3 laboratories, Komaba Open Laboratory of the University of Tokyo, National Cancer Center (NCC) and Molecular & Life Innovation of Tokyo University (MLI).
Fusing frontline expertise of genome, antibody and molecular pathology, FPR has made considerable achievements in antibody drug discovery and cancer stem cell study through exploring unique drug development targets with a completely new approach. While mounting an effort to accumulate relevant data, develop tools and assay technology, FPR deploys explanatory research to deliver innovative medicines based on deeper comprehension of human pathological state.
It is our mission is to determinedly tackle new and original study and technology with flexible management that allows investment for the future, and by developing a network of advanced research institutes as a far-sighted frontier in unprecedented research fields. We continue to explore this strategy believing the fruit of our studies leads to seeds of prospective first-in-class drug discovery and establishment of new assay technology.